Hao X - Search Results

1

Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.

Zou Z, Hao X, Zhang C, Li H, Dong G, Peng Y, Ma K, Guo Y, Shan L, Zhang Y, Liang L, Gu Y, Xing P, Li J. Zou Z, et al. Among authors: hao x. Thorac Cancer. 2022 Jan;13(1):107-116. doi: 10.1111/1759-7714.14232. Epub 2021 Dec 1. Thorac Cancer. 2022. PMID: 34851035 Free PMC article.

2

[Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer].

Lin L, Hao X, Li J, Wang Z, Wang Y, Wang H, Hu X, Zhang X. Lin L, et al. Among authors: hao x. Zhongguo Fei Ai Za Zhi. 2007 Dec 20;10(6):513-9. doi: 10.3779/j.issn.1009-3419.2007.06.14. Zhongguo Fei Ai Za Zhi. 2007. PMID: 21129311 Free article. Chinese.

3

[Analysis of chemotherapeutic efficacy after a failed regimen of epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small cell lung carcinoma].

Zhao LD, Li JL, Wang Y, Wang B, Wang HY, Hao XZ, Cui CX, Zhang XR, Shi YK. Zhao LD, et al. Zhonghua Yi Xue Za Zhi. 2011 Feb 15;91(6):366-9. Zhonghua Yi Xue Za Zhi. 2011. PMID: 21418906 Chinese.

4

[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].

Zhao LD, Li JL, Wang Y, Wang B, Wang HY, Hao XZ, Cui CX, Zhang XR, Shi YK. Zhao LD, et al. Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):217-21. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21575523 Chinese.

5

[Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].

Li B, Wang Y, Zhu HX, Li JL, Hu XS, Wang B, Hao XZ, Wang L, Zhang XR, Shi YK. Li B, et al. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):431-5. Zhonghua Zhong Liu Za Zhi. 2011. PMID: 21875483 Chinese.

6

[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].

Li J, Hao X, Wang Y, Zhang X, Shi Y. Li J, et al. Among authors: hao x. Zhongguo Fei Ai Za Zhi. 2012 Jan;15(1):44-8. doi: 10.3779/j.issn.1009-3419.2012.01.09. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22237124 Free PMC article. Chinese.

7

Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial.

Huang J, Fan QX, Chen L, Liu AN, Cai RG, Hao XZ, Wang JW, Sun Y. Huang J, et al. Chin Med J (Engl). 2011 Dec;124(23):4012-7. Chin Med J (Engl). 2011. PMID: 22340334 Clinical Trial.

8

[Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer].

Li J, Wang J, Hao X, Zhang X, Shi Y. Li J, et al. Among authors: hao x. Zhongguo Fei Ai Za Zhi. 2012 Mar;15(3):179-82. doi: 10.3779/j.issn.1009-3419.2012.03.08. Zhongguo Fei Ai Za Zhi. 2012. PMID: 22429582 Free PMC article. Chinese.

9

[Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer].

Zhao LD, Zhang XR, Li JL, Wang ZP, Wang Y, Hao XZ, Hu XS, Zhou SY, Sun Y, Shi YK. Zhao LD, et al. Zhonghua Yi Xue Za Zhi. 2012 Jun 12;92(22):1527-31. Zhonghua Yi Xue Za Zhi. 2012. PMID: 22944054 Chinese.

10

[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].

Wang Y, Li JL, Wang ZP, Hao XZ, Wang B, Zhang XR, Shi YK. Wang Y, et al. Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):780-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.013. Zhonghua Zhong Liu Za Zhi. 2012. PMID: 23291074 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,138 results

Search Page

Filters